体軸型脊椎関節炎におけるTNF阻害薬とIL-17阻害薬の治療継続率: 他施設共同比較解析
Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416
In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.
These findings are in agreement with two recent propensity-matched studies involving axSpA patients with previous TNFi exposure. This supports guidelines which recommend individualised care based on patient circumstances and preference. However, head-to-head studies are needed to determine the most appropriate individual treatment sequences and strategies.
